Development of Fluorophosphoramidate as a Biocompatibly Transformable Functional Group and its Application as a Phosphate Prodrug for Nucleoside Analogs

• DOI: 10.1002/cmdc.202200188
• Publication Date: 2022-04-08T02:54:51Z
• Authors: Yuki Yoshida; Ti Zheng; Wataru Tanabe; Fumiaki Tomoike; Fumitaka Hashiya; Tetsuro Suzuki; Shuto Hirota; Yuriko Saiki; Akira Horii; Akiyoshi Hirayama; Tomoyosi Soga; Yasuaki Kimura; Hiroshi Abe
• Keywords: 0301 basic medicine; 03 medical and health sciences; Neoplasms; Humans; Prodrugs; Antiviral Agents; Phosphates; 3. Good health

AbstractSynthetic phosphate‐derived functional groups are important for controlling the function of bioactive molecules in vivo. Herein we describe the development of a new type of biocompatible phosphate analog, a fluorophosphoramidate (FPA) functional group that has characteristic P−F and P−N bonds. We found that FPA with a primary amino group was relatively unstable in aqueous solution and was converted to a monophosphate, while FPA with a secondary amino group was stable. Furthermore, by improving the molecular design of FPA, we developed a reaction in which a secondary amino group is converted to a primary amino group in the intracellular environment and clarified that the FPA group functions as a phosphate prodrug of nucleoside. Various FPA‐gemcitabine derivatives were synthesized and their toxicity to cancer cells were evaluated. One of the FPA‐gemcitabine derivatives showed superior toxicity compared with gemcitabine and its ProTide prodrug, which methodology is widely used in various nucleoside analogs, including anti‐cancer and anti‐virus drugs.